Bildkälla: Stockfoto

Xspray Pharma Q4 2023: NDA-resubmission accepted by the FDA - Redeye

Redeye updates its outlook for Xspray following its Q4 report, and we highlight that the recently announced PDUFA-date at the end of July marks a significant catalyst for the stock.

Redeye updates its outlook for Xspray following its Q4 report, and we highlight that the recently announced PDUFA-date at the end of July marks a significant catalyst for the stock.
Börsvärldens nyhetsbrev
ANNONSER